Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions: Inclacumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Conditions: Type 2 Diabetes
Interventions: Mulberry Leaf Extract, Placebo; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Anesthesia
Interventions: Blood drawn; Diagnostic Test
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 40 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia
Interventions: cord clamping at 2 minutes, cord clamping at 5 minutes, cord milking; Procedure
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypogonadism, Male, Kidney Disease, Chronic
Interventions: Jatenzo Pill; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anemia, Sickle Cell
Interventions: NP Battery, MRI; Behavioral · Procedure
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more

Conditions: Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 30
States / cities: Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more

Conditions: Recovery of Hemoglobin and Iron Stores After Blood Donation
Interventions: ferrous gluconate; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: San Francisco, California • Farmington, Connecticut • Pittsburgh, Pennsylvania + 1 more

Conditions: Major Spine Surgery Procedure
Interventions: Masimo Radical-7; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hemorrhage
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 100 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions: Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Elective Cardiac Surgery
Interventions: CytoSorb; Device
Lead sponsor: CytoSorbents, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 20
States / cities: New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more

Conditions: Hemoglobins, Diagnostic Tests
Interventions: MyChart message; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 26
States / cities: Little Rock, Arkansas • National City, California • Spring Valley, California + 23 more

Conditions: Sickling Disorder Due to Hemoglobin S
Interventions: 131I-apamistmab, Sirolimus, Campath, Total Body Irradiation, Exchange Transfusion, Planar gamma imaging; Drug · Radiation · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more

Conditions: Anemia
Interventions: Oral Iron, sodium ferric gluconate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Orange County, California • Simi Valley, California + 5 more

Conditions: Healthy
Interventions: Rad-67 Pulse CO-Oximeter and DCI Mini sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, thiazolidinedione (TZD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,665 participants
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1984 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Darbepoetin alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 68
States / cities: Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more

Conditions: Diabetes Mellitus
Interventions: "Diabetes Report Card"; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: exercise; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 30 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Search by objective public record fields.

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Impact of Mulberry Leaf on Type 2 Diabetes

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

Placental Transfusion in Term Infants: A Pilot Study

Testosterone Treatment in Men With Chronic Kidney Disease

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Hemoglobin and Iron Recovery Study

Masimo Radical-7 Monitor a Useful Adjuvant During Major Spine Surgery

Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

Electronic Triggers: Messaging After A1C EHR Alert

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Rad-67 Repeatability and Reproducibility

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

New Ways to Help Patients Improve Their Diabetes Control

Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes